Pereira-Da Silva Maria Valeria, Di Nicola Maria Laura, Altomare Filiberto, Xu Wei, Tsang Richard, Laperriere Normand, Krema Hatem
Ocular Oncology Service Princess Margaret Cancer Center/University Health Network, Canada.
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.
Clin Transl Radiat Oncol. 2022 Oct 8;38:15-20. doi: 10.1016/j.ctro.2022.10.001. eCollection 2023 Jan.
To report the efficacy and toxicity of External beam Radiotherapy (EBRT) as a sole treatment for MALT and Follicular Primary Orbital and Ocular adnexal Lymphoma (POOAL).
Retrospective review of all POOAL patients treated with EBRT utilizing megavoltage photon or electron beam radiotherapy between 2003 and 2015. Patient demographics, tumour extent and pathology, radiotherapy techniques, and treatment outcomes were reviewed. The actuarial rates of tumour control and radiation toxicities were calculated using Kaplan-Meier estimates.
This study included 167 tumours, of which MALT lymphoma involved 149 (89 %). The conjunctiva and orbit were equally involved as the predominant site (48 %). Megavoltage photon radiotherapy was used in 60 % of predominantly orbital lymphoma and Electron beam with lens shielding in 77 % of the conjunctival lymphoma. The majority (95 %) were treated with a total dose of 25 Gy in 10 fractions. Local control rate was 98 % (CI: 93-100 %) at 5 years. The long-term RT toxicities included dry eye in 27 eyes (16 %) and cataract in 22 (13 %). None of the patients developed significant structural or functional radiation toxicity.
External Beam Radiotherapy, with lens shielding whenever indicated, at a dose of 20-30 Gy delivered over 10-20 fractions is an efficacious and safe primary treatment option for POOAL lymphoma, with excellent local control and low incidence of late manageable ocular toxicities.
报告外照射放疗(EBRT)作为黏膜相关淋巴组织(MALT)淋巴瘤和滤泡性原发性眼眶及眼附属器淋巴瘤(POOAL)的单一治疗方法的疗效和毒性。
回顾性分析2003年至2015年间接受兆伏级光子或电子束放疗的所有POOAL患者。回顾患者的人口统计学资料、肿瘤范围和病理、放疗技术及治疗结果。使用Kaplan-Meier估计法计算肿瘤控制和放射毒性的精算率。
本研究纳入167例肿瘤,其中MALT淋巴瘤149例(89%)。结膜和眼眶作为主要受累部位的比例相同(48%)。60%的主要为眼眶淋巴瘤患者采用兆伏级光子放疗,77%的结膜淋巴瘤患者采用带晶状体屏蔽的电子束放疗。大多数患者(95%)接受了25Gy分10次的总剂量治疗。5年时局部控制率为98%(CI:93-100%)。长期放疗毒性包括27只眼(16%)出现干眼,22只眼(13%)出现白内障。没有患者发生严重的结构或功能放射毒性。
外照射放疗,必要时进行晶状体屏蔽,剂量为20-30Gy分10-20次给予,是POOAL淋巴瘤一种有效且安全的主要治疗选择,局部控制良好,晚期可处理的眼部毒性发生率低。